Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2011

View Archived Issues

Sulfated hyaluronic acid shows preclinical promise to treat prostate cancer

Johnson & Johnson discloses new adenosine A2A receptor antagonists

Halozyme Therapeutics presents recombinant human proteins with collagenolytic effects

New glucocorticoid receptor modulators prepared

Vantia presents novel kallikrein-1 inhibitors

Allopurinol may improve outcomes in patients with ischemic stroke

Johnson & Johnson claims novel delta opioid receptor ligands

New lysophospholipid LPA1 receptor antagonists prepared at sanofi-aventis

Kaken Pharmaceutical obtains approval in Japan for additional doses and indication of Ebutol

InSite Vision reaches SPA agreement with FDA for phase III trial of AzaSite Plus and DexaSite

Peregrine Pharmaceuticals begins bavituximab combination trial in prostate cancer

Tigris Pharmaceuticals begins phase II trial of AFP-464 in ER-positive breast cancer

Eszopiclone effectively treats insomnia as add-on to escitalopram in GAD and to fluoxetine in MDD

TD-1211 safety and pharmacokinetics assessed in healthy volunteers and patients with OIC

Isconova begins phase I trial of its Matrix M adjuvant with seasonal influenza vaccine

Pharmasset begins phase IIa PSI-7977/daclatasvir study for hepatitis C genotypes 1, 2 and 3

MAP Pharmaceuticals submits NDA for Levadex to FDA

Epitomics signs agreement with Bayer Schering Pharma for antibody technology

EMA accepts for review Savient Pharmaceuticals' MAA for Krystexxa

Medicago to collaborate with U.S. army on Ebola vaccine

Mitsubishi Tanabe Pharma launches antiallergy agent bepotastine besilate in China and Indonesia

Sanofi and DNDi enter 3-year collaboration to research nine neglected tropical diseases

U.S. government requests proposal from Emergent BioSolutions for supply BioThrax anthrax vaccine

EMA and Health Canada recommend revaccination with Ixiaro vaccine due to batch recall

FDA approves Dificid for treatment of CDI-associated diarrhea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.